Results 91 to 100 of about 9,340 (184)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab

Drug Design, Development and Therapy, 2017
Corrado Pelaia,1 Alessandro Vatrella,2 Maria Teresa Busceti,1 Luca Gallelli,3 Rosa Terracciano,3 Rocco Savino,3 Girolamo Pelaia1 1Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia&rdquo ...
Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G   +6 more
doaj  

Comparative efficacy of mepolizumab and benralizumab in severe eosinophilic asthma: a retrospective cohort study. [PDF]

BMC Pulm Med
Huang WC, Shen YL, Cheng WC, Huang CW, Chen CH, Tu CY, Hsu WH.   +6 more
europepmc   +1 more source

Benralizumab reduces sputum ANCA in patients with eosinophilic granulomatosis with polyangiitis. [PDF]

ERJ Open Res
Mukherjee M, Tan NS, Huang C, Kim B, Radford K, Ju X, Venegas Garrido C, Kjarsgaard M, Rodríguez-Suárez E, Wechsler ME, Walker B, Börjesson Sjö L, Necander S, Ashkar A, Weidner J, Sehmi R, McCrae C, Khalidi N, Nair P.   +18 more
europepmc   +1 more source

Real-world sinonasal outcomes in patients with primary diffuse chronic rhinosinusitis treated with mepolizumab across polyp phenotypes. [PDF]

Front Immunol
Kumar N, Patel E, Marino MJ, Lal D.
europepmc   +1 more source

Six-Month Benralizumab Maintenance for Relapsing Chronic Eosinophilic Pneumonia Guided by Eosinophil Kinetics. [PDF]

Respirol Case Rep
Sumi T, Ishigooka T, Takeda K, Naraoka T, Shijubou N, Yamada Y, Chiba H.   +6 more
europepmc   +1 more source

Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR). [PDF]

Clin Transl Allergy
Alobid I, Seys SF, de Kinderen J, Hox V, Cavaliere C, Andrianakis A, Schneider S, Wagenmann M, Bruch M, Izquierdo-Domínguez A, Gonzalez-Compta X, Muñoz LP, Van Gerven L, Hellings PW, Mortuaire G, Burian M, Golet-Fors M, Moyaert M, Tomazic PV, Bettio G, de Vincentiis M, Diamant Z, Eckl-Dorna J, Mariën G, Masieri S, Morgenstern C, Scheckenbach K, Tu A, Rodriguez van Strahlen C, Bachert C, CHRINOSOR consortium.   +30 more
europepmc   +1 more source

Development of Pediatric Dosing for Mepolizumab in Severe Asthma Based on Extrapolation of Data From Adult Patients and a Phase II Open-Label Pediatric Trial. [PDF]

J Clin Pharmacol
Gupta A, Pouliquen IJ, Phipatanakul W, Austin D, Whelan G, Price RG, Finney-Hayward T, Derey S, Steinfeld J.   +8 more
europepmc   +1 more source

Trends of T2 and Non-T2 Cytokines During Mepolizumab Treatment in Different Asthma Patient Subgroups. [PDF]

Biomedicines
Zurlo M, Ambrosani F, Maule M, Cheema NA, Mascia F, Aparo A, Argentino G, Vaia R, Baiocchi A, Senna G, Friso S, Castagna A, Caminati M.   +12 more
europepmc   +1 more source

Using machine learning to define mepolizumab treatment response at 2 years in patients with chronic rhinosinusitis with nasal polyps. [PDF]

Front Allergy
Domínguez-Sosa MS, Cabrera-Ramírez MS, Marrero-Ramos MDC, Cabrera-López C, Carrillo-Díaz T, Benítez-Rosario J, Dávila-Quintana CD.   +6 more
europepmc   +1 more source

Marked Clinical and Functional Response to Tezepelumab After Failure of Anti-Interleukin-5 (Anti-IL-5) Therapy in Severe Asthma. [PDF]

Cureus
Fujimoto M, Yanagihara T, Sakaki Y, Fujita M.   +3 more
europepmc   +1 more source